Targeting menin for precision therapy in high-risk acute myeloid leukemia

Abdur Jamil; Zaheer Qureshi; Zain Mary El-Amir; Gillian Kupakuwana-Suk; Hamzah Akram; Mohsin Ahmad; Eric Huselton

doi:10.1016/j.lrr.2024.100495

Targeting menin for precision therapy in high-risk acute myeloid leukemia

Leuk Res Rep. 2024 Dec 18:23:100495. doi: 10.1016/j.lrr.2024.100495. eCollection 2025.

Authors

Abdur Jamil¹, Zaheer Qureshi², Zain Mary El-Amir³, Gillian Kupakuwana-Suk⁴, Hamzah Akram⁵, Mohsin Ahmad⁶, Eric Huselton⁷

Affiliations

¹ Department of Medicine, Samaritan Medical Centre Watertown, NY, USA.
² The Frank H. Netter M.D. School of Medicine at Quinnipiac University, Bridgeport, Connecticut, USA.
³ University of Michigan, Ann Arbor, MI, USA.
⁴ Leukemia Fellowship Program at The Ottawa Hospital Division of Hematology Department of Medicine University of Ottawa, Ottawa, Canada.
⁵ Hamilton Health Sciences, Hamilton, Ontario, Canada.
⁶ CHRISTUS Southeast Texas - St. Elizabeth Hospital, Beaumont, Texas, USA.
⁷ University of Rochester, Department of Hematology/Oncology, Rochester, NY, USA.

Abstract

Objective: This mini-review provides an overview of the current evidence for Revumenib, a first-in-class menin inhibitor, in treating AML with KMT2A rearrangements or NPM1 mutations. This therapy represents a promising advancement by selectively disrupting leukemogenic pathways.

Summary: The clinical promise of Revumenib in genetically defined AML highlights its potential role in shaping the future treatment landscape. This mini-review underscores the need for ongoing trials to define optimal dosing, safety protocols, and combination therapies, with the ultimate goal of establishing Revumenib as a standard of care for high-risk AML subsets.

Keywords: Acute myeloid leukemia; KMT2A; Menin inhibition therapy; Revumenib.

Publication types

Review